Abionic

Focus: Abionic is a Swiss diagnostics company specializing in rapid sepsis detection devices, operating at the early-stage biotech level. The company is Series A-funded and focused on point-of-care testing for infectious diseases.

Infectious Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

SERIES A

Open Jobs

About Abionic

AI assessmentNot Hiring

No open roles listed right now. Follow Abionic to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

12 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

IgE Test Panel

Allergic Asthma

N/A

Clinical Trials (1)

NCT04401631Analytical Validation of the abioSCOPE Device With an IgE Test Panel: Point-of-Care Precision, Sample Type Comparison and Method Correlation

N/A

Help build intelligence for Abionic

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Join a focused diagnostics innovator with a clear lead program (Pancreatic Stone Protein assay) backed by 6 clinical trials in high-need sepsis indication
Early-stage company offers equity upside potential and direct impact on product development before Series B scaling
Switzerland headquarters provides strong regulatory pathway to European markets with lower barrier to entry than US-only players

Watch Out For

Series A stage with no active job postings suggests limited near-term hiring and potential cash constraints typical of pre-revenue diagnostics companies
No disclosed financial data, revenue, or R&D intensity metrics make it difficult to assess stability or burn rate

Generated by Claude from Abionic's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Evaluation and Validation of Novel Diagnostic Tool for Allergists (AbioSCOPE)

Allergic Rhinitis

N/A

Clinical Trials (1)

NCT03599908Evaluation and Validation of Novel Diagnostic Tool for Allergists (AbioSCOPE)

N/A

abioSCOPE

Sepsis

N/A

Clinical Trials (1)

NCT05849935abioSCOPE PSP Reference Range Study; Extension of AB-PSP-003

N/A

Blood collection

Sepsis

N/A

Clinical Trials (1)

NCT04409561Reference Range for abioSCOPE® Device With the PSP Assay in a Generally Healthy Adult Population

N/A

Blood sampling

Sepsis

N/A

Clinical Trials (1)

NCT03474809Early Diagnostic of Sepsis and Potential Impact on Antibiotic Management Based on Serial.Pancreatic Stone Protein (PSP) Measured Using the AbioScope.

N/A

Blood Collection

Allergy

N/A

Clinical Trials (1)

NCT04442932abioSCOPE IgE Assay to Aid in the Diagnosis of Allergies

N/A

Prospective Study to Validate the Diagnostic Performance of IVD CAPSULE COVID-19-NP Test for the Det

COVID-19

N/A

Clinical Trials (1)

NCT05596032Prospective Study to Validate the Diagnostic Performance of IVD CAPSULE COVID-19-NP Test for the Detection of SARS-CoV-2

N/A

blood sample

Sepsis

N/A

Clinical Trials (1)

NCT04797117Analytical Validation of the abioSCOPE Device With a PSP Test: Point-of-Care Precision, Sample Type Comparison and Sample Stability

N/A

Blood Sampling

Sepsis

N/A

Clinical Trials (1)

NCT05627076Analytical Validation of the abioSCOPE Device With the IVD CAPSULE PSP Test: Comparison of PSP Values Measured With Venous Whole Blood and Those Measured With Arterial Whole Blood.

N/A

Blood sampling

Sepsis

N/A

Clinical Trials (1)

NCT04105699Evaluation of Immunoassay Measurements of Pancreatic Stone Protein Performed on abioSCOPE® Device With the PSP Assay on ICU Patients at Risk of Sepsis as an Aid in Identifying Sepsis

N/A

SARS-CoV-2 Detection Test

COVID-19

N/A

Pancreatic Stone Protein (PSP) Assay

Sepsis

N/A